SynthesisBreast cancer research and treatment2025
Association between ESR1 polymorphisms (XbaI & PvuII) and breast cancer risk: a comprehensive meta-analysis of case-control studies.
Synthesis in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is one of the most common malignancies worldwide with notable geographic variation in incidence and mortality. Its risk is shaped by both environmental and genetic factors. Among the genetic contributors, ESR1 intronic polymorphisms such as XbaI and PvuII have been associated with breast cancer susceptibility, though results across populations remain inconsistent.
aimIn light of these discrepancies, the present study aimed to comprehensively evaluate the association between ESR1 polymorphisms (XbaI and PvuII) and breast cancer risk using a meta-analytical approach, with particular attention to ethnicity-based subgroup effects and methodological rigor.
methodsA systematic review was conducted per PRISMA guidelines using PubMed, Semantic Scholar, and Google Scholar. Twenty-six studies on XbaI and 28 on PvuII polymorphisms were included based on set criteria. Genotype and allele data were extracted, with study quality checked via the Newcastle-Ottawa Scale. Studies deviating from Hardy-Weinberg Equilibrium were excluded. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated across multiple genetic models. Heterogeneity was evaluated using I
resultsMeta-analysis of ESR1 XbaI showed no significant association with breast cancer risk across all genetic models (e.g., allelic OR = 0.9957; p = 0.898), including ethnic subgroups (African, Asian, Caucasian). Moderate heterogeneity was noted, but sensitivity and publication bias analyses confirmed result stability. Similarly, ESR1 PvuII showed no overall association (e.g., allelic OR = 0.9755; p = 0.406); however, significant associations emerged in Africans (e.g., dominant OR = 1.7992; p = 0.012), suggesting ethnic-specific susceptibility. DISCUSSION &
conclusionWhile ESR1 XbaI and PvuII polymorphisms are not associated with overall breast cancer risk, the PvuII variant may influence susceptibility in African populations. These findings highlight the need for large, multi-ethnic studies with standardized methods to clarify population-specific genetic risks.
Indexed as
Identifiers
40779029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.